" />
Programmed cell death ligand 1 by clone 22C3:Imp:Pt:Tiss:Nar:Immune stain - CISMeF
Programmed cell death ligand 1 by clone 22C3:Imp:Pt:Tiss:Nar:Immune stainLOINC code
Preferred Label : Programmed cell death ligand 1 by clone 22C3:Imp:Pt:Tiss:Nar:Immune stain;
LOINC status : ACTIVE;
LOINC display name : PD-L1 by clone 22C3 Immune stain Nar (Tiss) [Interp];
LOINC long common name : PD-L1 by clone 22C3 [Interpretation] in Tissue by Immune stain Narrative;
LOINC short name : PD-L1 by 22C3 Tiss ImStn-Imp;
LOINC description : This term should be used to report the narrative impression of PD-L1 (CD274) protein
expression in tumor cells as determined by immune staining with anti-PD-L1 clone 22C3.
Patients with certain cancers, such as non-small cell lung cancer (NSCLC), whose tumors
are positive for PD-L1 by 22C3 may be eligible for anti-programmed death 1 (PD-1)
receptor antibody therapy, which effectively prevents the binding of PD-L1 to PD-1.
The percentage of viable tumor cells that show partial or complete PD-L1 membrane
staining is reported using [LOINC:83053-9], and the ordinal result for PD-L1 expression
using [LOINC: 83052-1]. This term was created for, but is not limited in use to, the
Dako PD-L1 22C3 pharmDx test kit, which, as of November 2016, is FDA-approved as a
companion diagnostic to assess whether patients with specific cancers are eligible
for pembrolizumab therapy.;
Has component